First patient dosed in Daiichi Sankyo’s Phase I DS1025 study

Phase 1DS1025Positive

AI Analysis

Summary

Daiichi Sankyo has dosed the first patient in a Phase I clinical trial of DS1025, an investigational therapy for adults with advanced or metastatic solid tumours with prior disease progression.

Clinical Trial Data

Phase

Phase I

Outcome Details

First patient dosed

Importance:3/10

Sentiment:

0.30

Phase 1OncologyTrial InitiationSolid Tumours

Related Companies

$DSKYF

Read the original article

Published by Clinical Trials Arena on August 28, 2026 9:02 AM

Read Original